Progress in the research of cognitive frailty in cerebral small vessel disease

doi:10.11817/j.issn.1673-9248.2024.02.015

Abstract

Abstract:

Cognitive frailty, characterized by both physical frailty and impaired cognitive function, poses a significant threat to overall health. Recent research has revealed a high prevalence of cognitive frailty among individuals with cerebral small vessel disease (CSVD), significantly impacting their daily functioning and quality of life. As the underlying processes and mechanisms of cognitive frailty in CSVD remain unclear, and effective treatment methods are lacking, it has become a prominent area of investigation in recent years. This review aims to provide an overview of the definition and mechanisms of cognitive frailty, the current state of domestic and international research on cognitive frailty in patients with CSVD, and the available treatments. By enhancing our understanding and building intervention strategies for cognitive frailty in patients with CSVD, we can prevent fatal and disabling outcomes.

Key words: Cerebral small vessel disease, Cognitive frailty, Mechanism, Treatment, Review

Jie Shen, Hongyang Xie, Cuiqiao Xia, Yonghua Huang. Progress in the research of cognitive frailty in cerebral small vessel disease[J]. Chinese Journal of Cerebrovascular Diseases(Electronic Edition), 2024, 18(02): 181-184.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhnxgbzz.cma-cmc.com.cn/EN/10.11817/j.issn.1673-9248.2024.02.015

https://zhnxgbzz.cma-cmc.com.cn/EN/Y2024/V18/I02/181

References 34

1	Campbell AJ, Buchner DM. For debate: unstable disability and the fluctuations of frailty[J]. Age Ageing, 1997, 26(4): 315-318.
2	Fried LP, Tangen CM, Walston J, et al. Frailty in older adults: evidence for a phenotype[J]. J Gerontol A Biol Sci Med Sci, 2001, 56(3): M146-M156.
3	Mitnitski AB, Mogilner AJ, Rockwood K. Accumulation of deficits as a proxy measure of aging[J]. ScientificWorldJournal, 2001, 1: 323-336.
4	Dent E, Kowal P, Hoogendijk EO. Frailty measurement in research and clinical practice: a review[J]. Eur J Intern Med, 2016, 31: 3-10.
5	Clegg A, Young J, Iliffe S, et al. Frailty in elderly people[J]. Lancet, 2013, 381(9868): 752-762.
6	Xia CQ, Xie HY, Huang YH, et al. Spatiotemporal gait characteristics during single- and dual-task walking are associated with the burden of cerebral small vessel disease[J]. Front Neurol, 2023, 14: 1285947.
7	Duering M, Biessels GJ, Wardlaw JM. Neuroimaging standards for research into small vessel disease-advances since 2013[J]. Lancet Neurol, 2023, 22(7): 602-618.
8	Kant IMJ, Mutsaerts HJMM, van Montfort SJT, et al. The association between frailty and MRI features of cerebral small vessel disease[J]. Sci Rep, 2019, 9(1): 11343.
9	Kelaiditi E, Cesari M, Canevelli M, et al. Cognitive frailty: rational and definition from an (I.A.N.A./I.A.G.G.) international consensus group[J]. J Nutr Health Aging, 2013, 17(9): 726-734.
10	Sargent L, Nalls M, Amella EJ, et al. Shared mechanisms for cognitive impairment and physical frailty: a model for complex systems[J]. Alzheimers Dement (N Y), 2020, 6(1): e12027.
11	Ruan Q, Yu Z, Chen M, et al. Cognitive frailty, a novel target for the prevention of elderly dependency[J]. Ageing Res Rev, 2015, 20: 1-10.
12	Chen LK, Arai H. Physio-cognitive decline as the accelerated aging phenotype[J]. Arch GerontolGeriatr, 2020, 88: 104051.
13	Sugimoto T, Sakurai T, Ono R, et al. Epidemiological and clinical significance of cognitive frailty: a mini review[J]. Ageing Res Rev, 2018, 44: 1-7.
14	Carini G, Musazzi L, Bolzetta F, et al. The potential role of miRNAs in cognitive frailty[J]. Front Aging Neurosci, 2021, 13: 763110.
15	Ipson BR, Fletcher MB, Espinoza SE, et al. Identifying exosome-derived microRNAs as candidate biomarkers of frailty[J]. J Frailty Aging, 2018, 7(2): 100-103.
16	Rusanova I, Diaz-Casado ME, Fernández-Ortiz M, et al. Analysis of plasma microRNAs as predictors and biomarkers of aging and frailty in humans[J]. Oxid Med Cell Longev, 2018, 2018: 7671850.
17	Xia X, Wang Y, Zheng JC. The microRNA-17 ~ 92 family as a key regulator of neurogenesis and potential regenerative therapeutics of neurological disorders[J]. Stem Cell Rev Rep, 2022, 18(2): 401-411.
18	Kim BS, Jung JY, Jeon JY, et al. Circulating hsa-miR-30e-5p, hsa-miR-92a-3p, and hsa-miR-223-3p may be novel biomarkers in systemic lupus erythematosus[J]. HLA, 2016, 88(4): 187-193.
19	Joilin G, Gray E, Thompson AG, et al. Identification of a potential non-coding RNA biomarker signature for amyotrophic lateral sclerosis[J]. Brain Commun, 2020, 2(1): fcaa053.
20	He JR, Zhang Y, Lu WJ, et al. Age-related frontal periventricular white matter hyperintensities and miR-92a-3p are associated with early-onset post-stroke depression[J]. Front Aging Neurosci, 2017, 9: 328.
21	Shi Y, Yi Z, Zhao P, et al. MicroRNA-532-5p protects against cerebral ischemia-reperfusion injury by directly targeting CXCL1[J]. Aging (Albany NY), 2021, 13(8): 11528-11541.
22	Mu J, Cheng X, Zhong S, et al. Neuroprotective effects of miR-532-5p against ischemic stroke[J]. Metab Brain Dis, 2020, 35(5): 753-763.
23	Mu L, Jiang L, Chen J, et al. Serum inflammatory factors and oxidative stress factors are associated with increased risk of frailty and cognitive frailty in patients with cerebral small vessel disease[J]. Front Neurol, 2022, 12: 786277.
24	Siejka TP, Srikanth VK, Hubbard RE, et al. Frailty and cerebral small vessel disease: a cross-sectional analysis of the tasmanian study of cognition and gait (TASCOG)[J]. J Gerontol A Biol Sci Med Sci, 2018, 73(2): 255-260.
25	Siejka TP, Srikanth VK, Hubbard RE, et al. White matter hyperintensities and the progression of frailty-the tasmanian study of cognition and gait[J]. J Gerontol A Biol Sci Med Sci, 2020, 75(8): 1545-1550.
26	Kant IMJ, Mutsaerts HJMM, van Montfort SJT, et al. The association between frailty and MRI features of cerebral small vessel disease[J]. Sci Rep, 2019, 9(1): 11343.
27	Sugimoto T, Ono R, Kimura A, et al. Cross-sectional association between cognitive frailty and white matter hyperintensity among memory clinic patients[J]. J Alzheimers Dis, 2019, 72(2): 605-612.
28	Yoshiura K, Fukuhara R, Ishikawa T, et al. Brain structural alterations and clinical features of cognitive frailty in Japanese community-dwelling older adults: the Arao study (JPSC-AD)[J]. Sci Rep, 2022, 12(1): 8202.
29	Zhào H, Wei W, Huang YH, et al. Cognitive frailty among elderly chinese patients with cerebral small vessel disease: a structural MRI study[J]. Front Med (Lausanne), 2020, 7: 397.
30	Liu Z, Hsu FC, Trombetti A, et al. Effect of 24-month physical activity on cognitive frailty and the role of inflammation: the LIFE randomized clinical trial[J]. BMC Med, 2018, 16(1): 185.
31	Yoon DH, Lee JY, Song W. Effects of resistance exercise training on cognitive function and physical performance in cognitive frailty: a randomized controlled trial[J]. J Nutr Health Aging, 2018, 22(8): 944-951.
32	Lv X, Niu H. Mesenchymal stem cell transplantation for the treatment of cognitive frailty[J]. J Nutr Health Aging, 2021, 25(6): 795-801.
33	Scassellati C, Ciani M, Galoforo AC, et al. Molecular mechanisms in cognitive frailty: potential therapeutic targets for oxygen-ozone treatment[J]. Mech Ageing Dev, 2020, 186: 111210.
34	Ruan Q, Ruan J, Zhang W, et al. Targeting NAD+ degradation: The therapeutic potential of flavonoids for Alzheimer's disease and cognitive frailty[J]. Pharmacol Res, 2018, 128: 345-358.

[1]	Huayue Yan, Zixiang Liu, Shaobo Zhou. Research progress of phosphoenolpyruvate carboxykinase-1 in malignant tumors [J]. Chinese Archives of General Surgery(Electronic Edition), 2024, 18(06): 452-456.
[2]	Huazhi Li, Guang Cao, Diangang Liu, Yajing Zhang. Clinical comparison of descending hepatectomy with different approaches for primary hepatocellular carcinoma [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2025, 19(01): 52-55.
[3]	Hao Chen, Meng Wang. Advances in clinicopathological features and treatment options of sig-ring cell carcinoma of the stomach [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2025, 19(01): 108-111.
[4]	Yuefang Xu, Wang Liu, Miaotian Zeng, Yushu Guo. Clinical efficacy of polymyxin B and polymyxin E in the treatment of surgical multi-drug resistant infections Security analysis [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2024, 18(06): 700-703.
[5]	Yuanyuan Yuan, Leqi Yue, Huaxing Zhang, Yan Wu, Quanhai Li. Advances in the distribution in lung tissue and therapeutic mechanisms of mesenchymal stem cells in respiratory system diseases models [J]. Chinese Journal of Cell and Stem Cell(Electronic Edition), 2024, 14(06): 374-381.
[6]	of Organ Transplantation of Chinese Medical Association Branch. Chinese practice guidelines for diagnosis and treatment of ischemic-type biliary lesion after liver transplantation [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2024, 13(06): 739-748.
[7]	Qiusheng Wang. Diagnosis and treatment strategy for benign biliary diseases [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2024, 13(06): 779-782.
[8]	Anti-Cancer Association China, Committee of Colorectal Cancer CACA the. CACA guidelines for holistic integrative management of anal cancer （2024 Edition） [J]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2024, 13(06): 441-449.
[9]	Zeyun Zhao, Jiannan Li, Min Wang. Research progress of neutrophil extracellular traps in colorectal cancer [J]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2024, 13(06): 524-528.
[10]	Xuefeng Zhou, Zheyi Dong, Zhe Feng, Guangyan Cai, Xiangmei Chen. Formulation protocol of guidelines for diagnosis and treatment of diabetic kidney disease with integrated traditional Chinese and Western medicine [J]. Chinese Journal of Kidney Disease Investigation(Electronic Edition), 2024, 13(06): 301-305.
[11]	Bin Shi, Yuan Si. Effect of Yiqiheluo formula combined with valsartan in the treatment of IgA nephropathy with deficiency of both qi and yin plus blood stasis syndrome [J]. Chinese Journal of Kidney Disease Investigation(Electronic Edition), 2024, 13(06): 306-312.
[12]	Wenkai Guo, Pengcheng Ji, Jingru Bi, Yuansheng Xie. Ten treatment measures for IgA nephropathy [J]. Chinese Journal of Kidney Disease Investigation(Electronic Edition), 2024, 13(06): 327-333.
[13]	Xuan Tie, Xiaole Su, Lihua Wang. Progress of research on the treatment of anti-neutrophil cytoplasmic antibody-associated vasculitis [J]. Chinese Journal of Kidney Disease Investigation(Electronic Edition), 2024, 13(06): 345-351.
[14]	Tianyu Wu, Zixuan Liu, Puxin Yang, Siming Jia, Kai Ding, Xiaodong Cheng, Yonglong Li, Wei Chen, Hongzhi Lyu, Qi Zhang. Progress in Conservative Treatment of Lumbar Disc Herniation [J]. Chinese Journal of Geriatric Orthopaedics and Rehabilitation(Electronic Edition), 2024, 10(06): 379-384.
[15]	Jingting Xu, Lu Kong. Mechanisms of resistance to PARP inhibitors in ovarian cancer and strategies to overcome such resistance [J]. Chinese Journal of Clinicians(Electronic Edition), 2024, 18(06): 584-588.

Please choose a citation manager

Content to export